1
|
Li J, Yang S, Wu Y, Wang R, Liu Y, Liu J, Ye Z, Tang R, Whiteway M, Lv Q, Yan L. Alternative Oxidase: From Molecule and Function to Future Inhibitors. ACS OMEGA 2024; 9:12478-12499. [PMID: 38524433 PMCID: PMC10955580 DOI: 10.1021/acsomega.3c09339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Revised: 01/31/2024] [Accepted: 02/07/2024] [Indexed: 03/26/2024]
Abstract
In the respiratory chain of the majority of aerobic organisms, the enzyme alternative oxidase (AOX) functions as the terminal oxidase and has important roles in maintaining metabolic and signaling homeostasis in mitochondria. AOX endows the respiratory system with flexibility in the coupling among the carbon metabolism pathway, electron transport chain (ETC) activity, and ATP turnover. AOX allows electrons to bypass the main cytochrome pathway to restrict the generation of reactive oxygen species (ROS). The inhibition of AOX leads to oxidative damage and contributes to the loss of adaptability and viability in some pathogenic organisms. Although AOXs have recently been identified in several organisms, crystal structures and major functions still need to be explored. Recent work on the trypanosome alternative oxidase has provided a crystal structure of an AOX protein, which contributes to the structure-activity relationship of the inhibitors of AOX. Here, we review the current knowledge on the development, structure, and properties of AOXs, as well as their roles and mechanisms in plants, animals, algae, protists, fungi, and bacteria, with a special emphasis on the development of AOX inhibitors, which will improve the understanding of respiratory regulation in many organisms and provide references for subsequent studies of AOX-targeted inhibitors.
Collapse
Affiliation(s)
- Jiye Li
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
- Institute
of Medicinal Biotechnology, Chinese Academy
of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Shiyun Yang
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
| | - Yujie Wu
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
| | - Ruina Wang
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
| | - Yu Liu
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
| | - Jiacun Liu
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
| | - Zi Ye
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
| | - Renjie Tang
- Beijing
South Medical District of Chinese PLA General Hospital, Beijing 100072, China
| | - Malcolm Whiteway
- Department
of Biology, Concordia University, Montreal, H4B 1R6 Quebec, Canada
| | - Quanzhen Lv
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
- Basic
Medicine Innovation Center for Fungal Infectious Diseases, (Naval Medical University), Ministry of Education, Shanghai 200433, China
- Key
Laboratory of Biosafety Defense (Naval Medical University), Ministry
of Education, Shanghai 200433, China
- Shanghai
Key Laboratory of Medical Biodefense, Shanghai 200433, China
| | - Lan Yan
- School
of Pharmacy, Naval Medical University, Shanghai 200433, China
- Basic
Medicine Innovation Center for Fungal Infectious Diseases, (Naval Medical University), Ministry of Education, Shanghai 200433, China
- Key
Laboratory of Biosafety Defense (Naval Medical University), Ministry
of Education, Shanghai 200433, China
- Shanghai
Key Laboratory of Medical Biodefense, Shanghai 200433, China
| |
Collapse
|
2
|
The potential of respiration inhibition as a new approach to combat human fungal pathogens. Curr Genet 2019; 65:1347-1353. [PMID: 31172256 PMCID: PMC6820612 DOI: 10.1007/s00294-019-01001-w] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Revised: 05/24/2019] [Accepted: 05/27/2019] [Indexed: 02/06/2023]
Abstract
The respiratory chain has been proposed as an attractive target for the development of new therapies to tackle human fungal pathogens. This arises from the presence of fungal-specific electron transport chain components and links between respiration and the control of virulence traits in several pathogenic species. However, as the physiological roles of mitochondria remain largely undetermined with respect to pathogenesis, its value as a potential new drug target remains to be determined. The use of respiration inhibitors as fungicides is well developed but has been hampered by the emergence of rapid resistance to current inhibitors. In addition, recent data suggest that adaptation of the human fungal pathogen, Candida albicans, to respiration inhibitors can enhance virulence traits such as yeast-to-hypha transition and cell wall organisation. We conclude that although respiration holds promise as a target for the development of new therapies to treat human fungal infections, we require a more detailed understanding of the role that mitochondria play in stress adaption and virulence.
Collapse
|
3
|
Minagawa N. [Mitochondria as targets of chemotherapy]. YAKUGAKU ZASSHI 2012; 132:1093-8. [PMID: 23037693 DOI: 10.1248/yakushi.12-00220-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Living organisms have developed a wide variety of energy metabolism to survive within the specialized environments. There is a remarkable diversity in mitochondrial electron transport system, which might be potential targets for chemotherapy. Atovaquone, clinically used to treat malaria and pneumocystis pneumonia, is a specific inhibitor of Qo site in the cytochrome bc(1) complex of Plasmodium falciparum and Pneumocystis jirovecii. Phytopathogenic fungus, Ascochyta viciae produces two antibiotics, ascochlorin and ascofuranone. Ascochlorin specifically binds to inhibit the electron transport of both Qi and Qo sites in cytochrome bc(1) complex. Besides the unique respiratory inhibition, further investigation is in progress to elucidate the effects on cancer cells. On the other hand, ascofuranone specifically inhibits cyanide-insensitive trypanosome alternative oxidase, which is a sole terminal oxidase in the mitochondrion of Trypanosoma brucei, causative of African trypanosomiasis. In vivo study suggests that ascofuranone is a promising candidate for chemotherapeutic agents to treat African trypanosomiasis.
Collapse
Affiliation(s)
- Nobuko Minagawa
- Department of Health Chemistry, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha, Niigata, Japan.
| |
Collapse
|